Upstream Bio, Inc. UPB R2K
Healthcare · Biotechnology · United States
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
READ MORE ›$8.36
-9.43% 1Y
Market & Price
Market Cap
$454.95M
Current Price
$8.36
High / Low (52W)
$32.60 / $7.36
Beta
-
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$6.26
Price to Book
1.33
P/S
136.95
EV/EBITDA
-0.94
Dividend Yield
-
Profitability & Returns
ROCE
-47.12%
ROE
-41.83%
ROA
-27.76%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-0.75
EPS (TTM)
$-2.90
Balance Sheet & Liquidity
Debt/Equity
0.37
Quick Ratio
21.74
Current Ratio
23.14
Debt
$1.11M
Total Assets
$353.77M
Current Assets
$351.80M
Working Capital
$338.35M
Ownership
Promoter Holding
14.88%
Chg in Prom Hold
-
FII / Inst Holding
90.10%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$161.49M
Total Revenue (TTM)
$3.32M
EBITDA
$-171.77M
Free Cash Flow
$-90.31M
Operating Cash Flow
$-139.96M
Shares Outstanding
54.42M
Gross Margin
100.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
33.04%
Profit 5Y
-166.99%
Revenue (YoY)
82.70%
Earnings (YoY)
-
PROS
- Compounding revenue at 33.0% over 5 years.
CONS
- Earnings shrank at -167.0% CAGR over 5 years.
- Trading 74.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | UPB Upstream Bio, Inc. R2K | 8.36 | - | $454.95M | - | -47.12% | -41.83% | 33.04% | -166.99% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 621.00K | 640.00K | 510.00K | - | - | 566.00K | 937.00K | 683.00K | 668.00K | 1.03M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | 32.58M | 45.28M | 38.52M | 46.84M | 44.65M |
| Operating Income | - | - | -9.39M | -15.01M | -17.54M | - | - | -32.01M | -44.35M | -37.83M | -46.17M | -43.62M |
| EBITDA | - | - | - | - | - | - | - | -31.97M | -44.30M | -37.79M | -46.11M | -43.57M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | -27.27M | -39.97M | -33.75M | -42.46M | -40.59M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -3.06M | -2.54M | -3.10M | -10.89M | -14.68M | - | - | -27.27M | -39.97M | -33.75M | -42.46M | -40.59M |
| Diluted EPS | - | - | -2.11 | -4.68 | -6.50 | - | - | -0.51 | -0.74 | -0.63 | -0.78 | -0.75 |
| R&D Expense | - | - | 7.79M | 11.69M | 14.07M | 15.43M | - | 25.80M | 37.87M | 32.98M | - | 36.56M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 1.21M | 2.38M | 2.37M | 2.85M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 25.12M | 42.49M | 80.13M | 163.22M |
| Operating Income | -23.91M | -40.11M | -77.76M | -160.36M |
| EBITDA | -23.90M | -40.05M | -77.67M | -160.17M |
| Interest Expense | - | - | - | - |
| Pretax Income | -23.87M | -20.54M | -62.81M | -143.44M |
| Tax Provision | - | - | - | - |
| Net Income | -23.87M | -20.54M | -62.81M | -143.44M |
| Diluted EPS | -0.66 | -1.05 | -1.17 | -2.66 |
| R&D Expense | - | 31.80M | 62.97M | 136.81M |
Compounded Sales Growth
| 5 Years: | 33.04% |
| 1 Year: | 82.70% |
Compounded Profit Growth
| 5 Years: | -166.99% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -9.43% |
| 6 Months: | -71.00% |
| 3 Months: | +8.85% |
| 1 Month: | -9.03% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 18.48M | 117.20M | 481.72M | 353.77M |
| Current Assets | 18.31M | 117.00M | 479.16M | 351.80M |
| Cash & Equivalents | 17.05M | 25.83M | 325.89M | 101.58M |
| Inventory | - | - | - | - |
| Receivables | 412.00K | 98.00K | 613.00K | 668.00K |
| Total Liabilities | 124.63M | 240.32M | 11.87M | 14.00M |
| Current Liabilities | 4.86M | 6.51M | 10.74M | 13.45M |
| Long Term Debt | - | - | - | - |
| Total Debt | 94.00K | 45.00K | 1.83M | 1.27M |
| Total Equity | -106.16M | -123.13M | 469.85M | 339.77M |
| Shares Outstanding | 51.34M | 51.34M | 53.60M | 54.24M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -19.02M | -37.93M | -59.17M | -133.28M |
| Investing Cash Flow | -82.00K | -82.84M | -59.48M | -93.48M |
| Financing Cash Flow | 9.96M | 129.55M | 418.91M | 2.44M |
| Capital Expenditure | -82.00K | -144.00K | -511.00K | -165.00K |
| Free Cash Flow | -19.10M | -38.07M | -59.68M | -133.44M |
| Net Change in Cash | -9.14M | 8.78M | 300.25M | -224.31M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | -1,972.7% | -1,685.5% | -3,281.2% | -5,618.8% |
| Net Margin % | -1,969.3% | -862.9% | -2,650.0% | -5,026.0% |
| ROE % | 22.5% | 16.7% | -13.4% | -42.2% |
| ROCE % | -175.5% | -36.2% | -16.5% | -47.1% |
Shareholding Pattern
Insiders
14.88%
Institutions
90.10%
Public Float
105.85%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.89% | 8.10M | $67.73M |
| 2 | Orbimed Advisors LLC. | 10.46% | 5.69M | $47.60M |
| 3 | Blackrock Inc. | 6.19% | 3.37M | $28.18M |
| 4 | Decheng Capital LLC | 5.01% | 2.72M | $22.78M |
| 5 | Enavate Sciences Gp, LLC | 4.52% | 2.46M | $20.56M |
| 6 | Vanguard Capital Management LLC | 3.44% | 1.87M | $15.66M |
| 7 | Y Intercept (Hong Kong) Ltd | 1.84% | 1.00M | $8.37M |
| 8 | Federated Hermes, Inc. | 1.80% | 979.76K | $8.19M |
| 9 | Geode Capital Management, LLC | 1.75% | 950.62K | $7.95M |
| 10 | Millennium Management Llc | 1.72% | 937.32K | $7.84M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for UPB
No recent headlines available.